Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease

Abuirmeileh, A., Harkavyi, A., Lever, R., Biggs, C.S. and Whitton, P.S. 2007. Urocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease. Journal of Neuroinflammation. 4, p. 19.

TitleUrocortin, a CRF-like peptide, restores key indicators of damage in the substantia nigra in a neuroinflammatory model of Parkinson's disease
AuthorsAbuirmeileh, A., Harkavyi, A., Lever, R., Biggs, C.S. and Whitton, P.S.
Abstract

We have recently observed that the corticotrophin releasing hormone (CRF) related peptide urocortin (UCN) reverses key features of nigrostriatal damage in the hemiparkinsonian 6-hydroxydopamine lesioned rat. Here we have studied whether similar effects are also evident in the lipopolysaccaride (LPS) neuroinflammatory paradigm of Parkinson's disease (PD). To do this we have measured restoration of normal motor behaviour, retention of nigral dopamine (DA) and also tyrosine hydroxylase (TH) activity. Fourteen days following intranigral injections of LPS and UCN, rats showed only modest circling after DA receptor stimulation with apomorphine, in contrast to those given LPS and vehicle where circling was pronounced. In separate experiments, rats received UCN seven days following LPS, and here apomorphine challenge caused near identical circling intensity to those that received LPS and UCN concomitantly. In a similar and consistent manner with the preservation of motor function, UCN 'protected' the nigra from both DA depletion and loss of TH activity, indicating preservation of DA cells. The effects of UCN were antagonised by the non-selective CRF receptor antagonist α-helical CRF and were not replicated by the selective CRF2 ligand UCN III. This suggests that UCN is acting via CRF1 receptors, which have been shown to be anti-inflammatory in the periphery. Our data therefore indicate that UCN is capable of maintaining adequate nigrostriatal function in vivo, via CRF1 receptors following a neuro-inflammatory challenge. This has potential therapeutic implications in PD.

JournalJournal of Neuroinflammation
Journal citation4, p. 19
ISSN1742-2094
Year21 Jul 2007
PublisherPubMed Central
Digital Object Identifier (DOI)doi:10.1186/1742-2094-4-19
Publication dates
Published21 Jul 2007

Related outputs

Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2018. Quin-C1: a selective Fpr2 agonist that shifts microglial phenotype following LPS and Aβ1-42 exposure. Alzheimer's Research UK Conference. London 20 - 22 Mar 2018

Reversal of β-amyloid induced microglial activation by an agonist of Fpr2
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Reversal of β-amyloid induced microglial activation by an agonist of Fpr2. British Pharmacological Society: Pharmacology 2017. London 11 - 14 Dec 2017

Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Activation of the pro-resolving receptor Fpr2 attenuates inflammatory microglial activation. BNA Festival of Neuroscience. Birmingham 10 - 14 Apr 2017 Sage.

Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects
Wickstead, E., Getting, S.J., Biggs, C.S. and McArthur, S. 2017. Fpr2 and neuroinflammation: selective agonists with synergistic anti-oxidative and pro-resolving effects. World Congress on Inflammation. London 08 - 13 Jul 2017

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S. and Whitton, P.S. 2008. Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation. 5 (1), p. 19.

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease
Abuirmeileh, A., Lever, R., Kingsbury, A.E., Lees, A.J., Locke, I.C., Knight, R.A., Chowdrey, H.S., Biggs, C.S. and Whitton, P.S. 2007. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease. European Journal of Neuroscience. 26 (2), pp. 417-423.

Evidence for a neuroprotective role of the CRH-like peptide, urocortin, in the 6-hydroxydopamine treated rat
Biggs, C.S., Locke, I.C., Knight, R.A., Chowdrey, H.S. and Whitton, P.S. 2005. Evidence for a neuroprotective role of the CRH-like peptide, urocortin, in the 6-hydroxydopamine treated rat. 18th National Meeting of the British Neuroscience Association. Brighton, UK 03-06 Apr 2005

Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model
Biggs, C.S., Abuirmeileh, A., Locke, I.C., Knight, R.A., Chowdrey, H.S. and Whitton, P.S. 2005. Urocortin attenuates key indicators of nigrostriatal pathway destruction in a rat hemiparkinsonian model. Proceedings of the British Pharmacological Society. 3 (4).

Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo
Getting, S.J., Segieth, J., Ahmad, S., Biggs, C.S. and Whitton, P.S. 1996. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Research. 717 (1-2), pp. 196-199.

Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats
Segieth, J., Getting, S.J., Biggs, C.S. and Whitton, P.S. 1995. Nitric oxide regulates excitatory amino acid release in a biphasic manner in freely moving rats. Neuroscience Letters. 200 (2), pp. 101-104.

Permalink - https://westminsterresearch.westminster.ac.uk/item/91q36/urocortin-a-crf-like-peptide-restores-key-indicators-of-damage-in-the-substantia-nigra-in-a-neuroinflammatory-model-of-parkinson-s-disease


Share this
Tweet
Email